Published in Am J Physiol Heart Circ Physiol on November 11, 2011
Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS (2012) 1.44
The effects of hypertension on the cerebral circulation. Am J Physiol Heart Circ Physiol (2013) 1.25
Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke. Curr Pharm Des (2012) 1.03
Targeted drug delivery to treat pain and cerebral hypoxia. Pharmacol Rev (2013) 1.01
Disruption in the Blood-Brain Barrier: The Missing Link between Brain and Body Inflammation in Bipolar Disorder? Neural Plast (2015) 0.88
Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr Pharm Des (2014) 0.88
Targeting transporters: promoting blood-brain barrier repair in response to oxidative stress injury. Brain Res (2015) 0.82
Physiology and pathophysiology of the blood-brain barrier: P-glycoprotein and occludin trafficking as therapeutic targets to optimize central nervous system drug delivery. J Investig Med (2012) 0.82
Drug delivery to the ischemic brain. Adv Pharmacol (2014) 0.82
Neurovascular unit in chronic pain. Mediators Inflamm (2013) 0.80
P-glycoprotein trafficking as a therapeutic target to optimize CNS drug delivery. Adv Pharmacol (2014) 0.77
Early Loss of Blood-Brain Barrier Integrity Precedes NOX2 Elevation in the Prefrontal Cortex of an Animal Model of Psychosis. Mol Neurobiol (2016) 0.76
Peptides at the blood brain barrier: Knowing me knowing you. Peptides (2015) 0.76
Role of Transporters in Central Nervous System Drug Delivery and Blood-Brain Barrier Protection: Relevance to Treatment of Stroke. J Cent Nerv Syst Dis (2017) 0.75
Effects of Muscone on the Expression of P-gp, MMP-9 on Blood-Brain Barrier Model In Vitro. Cell Mol Neurobiol (2015) 0.75
Hypoxic Stress and Inflammatory Pain Disrupt Blood-Brain Barrier Tight Junctions: Implications for Drug Delivery to the Central Nervous System. AAPS J (2017) 0.75
Nitroxidative Signaling Mechanisms in Pathological Pain. Trends Neurosci (2016) 0.75
Effects of hepatic ischemia-reperfusion injury on the blood-brain barrier permeability to [(14)C] and [(13)C]sucrose. Metab Brain Dis (2017) 0.75
The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron (2008) 10.19
Structure and function of the blood-brain barrier. Neurobiol Dis (2009) 7.64
The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev (2005) 7.56
Occludin is a functional component of the tight junction. J Cell Sci (1996) 3.90
The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci (2009) 3.06
Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci (2008) 2.65
The use of total protein stains as loading controls: an alternative to high-abundance single-protein controls in semi-quantitative immunoblotting. J Neurosci Methods (2008) 2.54
A newly identified role for superoxide in inflammatory pain. J Pharmacol Exp Ther (2004) 2.21
Chemistry and antihypertensive effects of tempol and other nitroxides. Pharmacol Rev (2008) 1.91
Occludin: structure, function and regulation. Adv Drug Deliv Rev (2005) 1.73
Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery. Ther Deliv (2011) 1.57
Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol (2001) 1.54
Increase in blood-brain barrier permeability, oxidative stress, and activated microglia in a rat model of blast-induced traumatic brain injury. J Neurosci Res (2010) 1.45
The blood-brain barrier is continuously open for several weeks following transient focal cerebral ischemia. Neuroscience (2008) 1.42
The role of reactive oxygen species in capsaicin-induced mechanical hyperalgesia and in the activities of dorsal horn neurons. Pain (2007) 1.41
Superoxide, peroxynitrite and oxidative/nitrative stress in inflammation. Biochem Soc Trans (2006) 1.35
Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation. J Cereb Blood Flow Metab (2010) 1.34
A peroxynitrite-dependent pathway is responsible for blood-brain barrier permeability changes during a central nervous system inflammatory response: TNF-alpha is neither necessary nor sufficient. J Immunol (2007) 1.29
Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J Pharmacol Exp Ther (2007) 1.29
Transforming growth factor-beta signaling alters substrate permeability and tight junction protein expression at the blood-brain barrier during inflammatory pain. J Cereb Blood Flow Metab (2009) 1.22
Occludin oligomeric assemblies at tight junctions of the blood-brain barrier are altered by hypoxia and reoxygenation stress. J Neurochem (2009) 1.22
Blood-brain barrier tight junctions are altered during a 72-h exposure to lambda-carrageenan-induced inflammatory pain. Am J Physiol Heart Circ Physiol (2002) 1.20
Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein. J Neurochem (2007) 1.18
TEMPOL, a membrane-permeable radical scavenger, attenuates peroxynitrite- and superoxide anion-enhanced carrageenan-induced paw edema and hyperalgesia: a key role for superoxide anion. Eur J Pharmacol (2006) 1.17
Angiotensin II induced cerebral microvascular inflammation and increased blood-brain barrier permeability via oxidative stress. Neuroscience (2010) 1.13
Tight junctions contain oligomeric protein assembly critical for maintaining blood-brain barrier integrity in vivo. J Neurochem (2007) 1.12
Occludin oligomeric assembly at tight junctions of the blood-brain barrier is disrupted by peripheral inflammatory hyperalgesia. J Neurochem (2008) 1.07
Alterations in blood-brain barrier ICAM-1 expression and brain microglial activation after lambda-carrageenan-induced inflammatory pain. Am J Physiol Heart Circ Physiol (2005) 1.04
Occludin protein family: oxidative stress and reducing conditions. Antioxid Redox Signal (2011) 1.04
Inflammatory pain signals an increase in functional expression of organic anion transporting polypeptide 1a4 at the blood-brain barrier. J Pharmacol Exp Ther (2010) 1.02
Western blot analysis for nitrotyrosine protein adducts in livers of saline-treated and acetaminophen-treated mice. Toxicol Sci (2000) 0.97
Quantification of early blood-brain barrier disruption by in situ brain perfusion technique. Brain Res Brain Res Protoc (2001) 0.94
Nociceptive inhibition prevents inflammatory pain induced changes in the blood-brain barrier. Brain Res (2008) 0.93
Redox-sensitivity of the dimerization of occludin. Cell Mol Life Sci (2009) 0.93
The oligomerization of the coiled coil-domain of occludin is redox sensitive. Ann N Y Acad Sci (2009) 0.93
Blood-brain barrier equilibration of codeine in rats studied with microdialysis. Pharm Res (1998) 0.92
Effect of lambda-carrageenan-induced inflammatory pain on brain uptake of codeine and antinociception. Brain Res (2004) 0.90
CNS penetration of small molecules following local inflammation, widespread systemic inflammation or direct injury to the nervous system. Life Sci (2009) 0.89
Nitric oxide mediates hypoxia-induced changes in paracellular permeability of cerebral microvasculature. Am J Physiol Heart Circ Physiol (2003) 0.86
Diclofenac attenuates the regional effect of lambda-carrageenan on blood-brain barrier function and cytoarchitecture. J Pharmacol Exp Ther (2008) 0.83
Superoxide reduction of a disulfide: a model of intracellular redox modulation? Biochem Biophys Res Commun (1994) 0.80
The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev (2005) 7.56
Cerebral microvascular changes in permeability and tight junctions induced by hypoxia-reoxygenation. Am J Physiol Heart Circ Physiol (2002) 1.79
Bioapplications of RAFT polymerization. Chem Rev (2009) 1.59
Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery. Ther Deliv (2011) 1.57
The generic enhancement of photochromic dye switching speeds in a rigid polymer matrix. Nat Mater (2005) 1.52
Calcium modulation of adherens and tight junction function: a potential mechanism for blood-brain barrier disruption after stroke. Stroke (2002) 1.52
Nicotine increases in vivo blood-brain barrier permeability and alters cerebral microvascular tight junction protein distribution. Brain Res (2004) 1.48
Effects of hypoxia-reoxygenation on rat blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol (2003) 1.45
Novel CenterCross and MultiCross devices for the treatment of infrainguinal chronic total occlusions: initial single-centre experience. EuroIntervention (2016) 1.38
Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation. J Cereb Blood Flow Metab (2010) 1.34
Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations. Am J Physiol Heart Circ Physiol (2005) 1.28
Development of neuropeptide drugs that cross the blood-brain barrier. NeuroRx (2005) 1.27
In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem (2006) 1.25
Well-defined protein-polymer conjugates via in situ RAFT polymerization. J Am Chem Soc (2007) 1.24
Transforming growth factor-beta signaling alters substrate permeability and tight junction protein expression at the blood-brain barrier during inflammatory pain. J Cereb Blood Flow Metab (2009) 1.22
Occludin oligomeric assemblies at tight junctions of the blood-brain barrier are altered by hypoxia and reoxygenation stress. J Neurochem (2009) 1.22
Protein kinase C activation modulates reversible increase in cortical blood-brain barrier permeability and tight junction protein expression during hypoxia and posthypoxic reoxygenation. J Cereb Blood Flow Metab (2010) 1.21
Smoking and ischemic stroke: a role for nicotine? Trends Pharmacol Sci (2002) 1.18
Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein. J Neurochem (2007) 1.18
An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke (2012) 1.18
Hypoxia/aglycemia alters expression of occludin and actin in brain endothelial cells. Biochem Biophys Res Commun (2005) 1.17
Efficacy and mechanism of action of turmeric supplements in the treatment of experimental arthritis. Arthritis Rheum (2006) 1.16
Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke (2008) 1.15
Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J Neurosci Res (2009) 1.14
Mannitol opening of the blood-brain barrier: regional variation in the permeability of sucrose, but not 86Rb+ or albumin. Brain Res (2004) 1.13
Tight junctions contain oligomeric protein assembly critical for maintaining blood-brain barrier integrity in vivo. J Neurochem (2007) 1.12
Temperature-responsive self-assembled monolayers of oligo(ethylene glycol): control of biomolecular recognition. ACS Nano (2008) 1.09
Nicotine and cotinine modulate cerebral microvascular permeability and protein expression of ZO-1 through nicotinic acetylcholine receptors expressed on brain endothelial cells. J Pharm Sci (2002) 1.09
RAFT and click chemistry: a versatile approach to well-defined block copolymers. Chem Commun (Camb) (2006) 1.08
Occludin oligomeric assembly at tight junctions of the blood-brain barrier is disrupted by peripheral inflammatory hyperalgesia. J Neurochem (2008) 1.07
Reversible siRNA-polymer conjugates by RAFT polymerization. Chem Commun (Camb) (2008) 1.06
Activation of PKC modulates blood-brain barrier endothelial cell permeability changes induced by hypoxia and posthypoxic reoxygenation. Am J Physiol Heart Circ Physiol (2005) 1.06
Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers. Curr Pharm Des (2013) 1.03
Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke. Curr Pharm Des (2012) 1.03
CNS drug delivery: opioid peptides and the blood-brain barrier. AAPS J (2006) 1.02
Inflammatory pain signals an increase in functional expression of organic anion transporting polypeptide 1a4 at the blood-brain barrier. J Pharmacol Exp Ther (2010) 1.02
Protection against hypoxia-induced increase in blood-brain barrier permeability: role of tight junction proteins and NFkappaB. J Cell Sci (2003) 1.01
Targeted drug delivery to treat pain and cerebral hypoxia. Pharmacol Rev (2013) 1.01
Comparative changes in the blood-brain barrier and cerebral infarction of SHR and WKY rats. Am J Physiol Regul Integr Comp Physiol (2007) 1.00
An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway. J Neurosci (2013) 1.00
Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. Curr Pharm Des (2012) 0.98
Reoxygenation stress on blood-brain barrier paracellular permeability and edema in the rat. Microvasc Res (2007) 0.97
P-glycoprotein trafficking at the blood-brain barrier altered by peripheral inflammatory hyperalgesia. J Neurochem (2012) 0.97
Hypoxia-inducible factor and nuclear factor kappa-B activation in blood-brain barrier endothelium under hypoxic/reoxygenation stress. J Neurochem (2005) 0.96
In situ formation of protein-polymer conjugates through reversible addition fragmentation chain transfer polymerization. Angew Chem Int Ed Engl (2007) 0.96
One-pot conversion of RAFT-generated multifunctional block copolymers of HPMA to doxorubicin conjugated acid- and reductant-sensitive crosslinked micelles. Biomacromolecules (2008) 0.94
Synthesis of various glycopolymer architectures via RAFT polymerization: from block copolymers to stars. Biomacromolecules (2006) 0.94
Nociceptive inhibition prevents inflammatory pain induced changes in the blood-brain barrier. Brain Res (2008) 0.93
Modulation of cerebral microvascular permeability by endothelial nicotinic acetylcholine receptors. Am J Physiol Heart Circ Physiol (2005) 0.91
Pain and the blood-brain barrier: obstacles to drug delivery. Adv Drug Deliv Rev (2003) 0.91
Poly(vinyl alcohol) star polymers prepared via MADIX/RAFT polymerisation. Chem Commun (Camb) (2004) 0.90
Biphasic cytoarchitecture and functional changes in the BBB induced by chronic inflammatory pain. Brain Res (2006) 0.90
RAFT polymerization and thiol chemistry: a complementary pairing for implementing modern macromolecular design. Macromol Rapid Commun (2011) 0.90
Effect of lambda-carrageenan-induced inflammatory pain on brain uptake of codeine and antinociception. Brain Res (2004) 0.90
Consistent experimental and theoretical evidence for long-lived intermediate radicals in living free radical polymerization. J Am Chem Soc (2004) 0.89
The importance of nanoparticle shape in cancer drug delivery. Expert Opin Drug Deliv (2014) 0.88
Efficient usage of thiocarbonates for both the production and the biofunctionalization of polymers. Macromol Rapid Commun (2009) 0.88
Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr Pharm Des (2014) 0.88
New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting. Clin Cancer Res (2005) 0.87
Synthesis and bioactivity of poly(HPMA)-lysozyme conjugates: the use of novel thiazolidine-2-thione coupling chemistry. Org Biomol Chem (2009) 0.87
Orthopedic surgery and bone fracture pain are both significantly attenuated by sustained blockade of nerve growth factor. Pain (2015) 0.87
One-pot synthesis and biofunctionalization of glycopolymers via RAFT polymerization and thiol-ene reactions. Chem Commun (Camb) (2009) 0.86
Multidrug resistance protein 1-mediated transport of saquinavir by microglia. Neuroreport (2004) 0.86
Nitric oxide mediates hypoxia-induced changes in paracellular permeability of cerebral microvasculature. Am J Physiol Heart Circ Physiol (2003) 0.86
Synthesis of versatile thiol-reactive polymer scaffolds via RAFT polymerization. Biomacromolecules (2008) 0.86
Shell-cross-linked vesicles synthesized from block copolymers of Poly(D,L-lactide) and Poly(N-isopropyl acrylamide) as thermoresponsive nanocontainers. Langmuir (2004) 0.86
Using fluorescence lifetime imaging microscopy to monitor theranostic nanoparticle uptake and intracellular doxorubicin release. ACS Nano (2013) 0.86
Protection against hypoxia-induced blood-brain barrier disruption: changes in intracellular calcium. Am J Physiol Cell Physiol (2003) 0.85
Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers. Mol Pharm (2013) 0.84
Regulation of P-glycoprotein by human immunodeficiency virus-1 in primary cultures of human fetal astrocytes. J Neurosci Res (2011) 0.84
Intravascular ultrasound evaluation of JETSTREAM atherectomy removal of superficial calcium in peripheral arteries. EuroIntervention (2015) 0.83
Diclofenac attenuates the regional effect of lambda-carrageenan on blood-brain barrier function and cytoarchitecture. J Pharmacol Exp Ther (2008) 0.83
Amphiphilic block copolymers based on poly(2-acryloyloxyethyl phosphorylcholine) prepared via RAFT polymerisation as biocompatible nanocontainers. Macromol Biosci (2004) 0.83
Effect of guanidino modification and proline substitution on the in vitro stability and blood-brain barrier permeability of endomorphin II. J Pharm Sci (2002) 0.83
Acetaminophen modulates P-glycoprotein functional expression at the blood-brain barrier by a constitutive androstane receptor-dependent mechanism. Mol Pharmacol (2013) 0.83
Shell-cross-linked micelles containing cationic polymers synthesized via the RAFT process: toward a more biocompatible gene delivery system. Biomacromolecules (2007) 0.82
Physiology and pathophysiology of the blood-brain barrier: P-glycoprotein and occludin trafficking as therapeutic targets to optimize central nervous system drug delivery. J Investig Med (2012) 0.82
Functional iron oxide magnetic nanoparticles with hyperthermia-induced drug release ability by using a combination of orthogonal click reactions. Angew Chem Int Ed Engl (2013) 0.82
Biodegradable star polymers functionalized with beta-cyclodextrin inclusion complexes. Biomacromolecules (2009) 0.81
Functional disulfide-stabilized polymer-protein particles. Biomacromolecules (2009) 0.81
Synthesis, characterization, and multilayer assembly of pH sensitive graphene-polymer nanocomposites. Langmuir (2010) 0.81
An approach to biodegradable star polymeric architectures using disulfide coupling. Chem Commun (Camb) (2008) 0.81
Branched polymer-protein conjugates made from mid-chain-functional P(HPMA). Biomacromolecules (2009) 0.81
Conjugation of low molecular weight poly(ethylene glycol) to biphalin enhances antinociceptive profile. J Pharm Sci (2003) 0.81
Pluronic p85 block copolymer enhances opioid peptide analgesia. J Pharmacol Exp Ther (2002) 0.81
Simultaneous polymerization-induced self-assembly (PISA) and guest molecule encapsulation. Macromol Rapid Commun (2013) 0.81
Viability of microvascular endothelial cells to direct exposure of formalin, lambda-carrageenan, and complete Freund's adjuvant. Eur J Pharmacol (2002) 0.81